LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Is LUTATHERA a Treatment Option for You?

If your health care professional has told you that your GEP-NET has grown or spread, LUTATHERA® (lutetium Lu 177 dotatate) injection for intravenous use may be a treatment option for you. Talk to your health care professional to find out more.

To get some ideas on what to talk to your health care professional about, please take a look at the helpful information inside.

What is LUTATHERA?

LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut.

IMPORTANT SAFETY INFORMATION

What are some important things to know about the safety of LUTATHERA?

LUTATHERA is associated with some serious safety considerations, and in some cases these may require your healthcare provider to adjust or stop your treatment. You should always follow your healthcare provider's instructions. Safety considerations include:

- **Radiation exposure:** Treatment with LUTATHERA will expose you to radiation which can contribute to your long-term radiation exposure. Overall radiation exposure is associated with an increased risk for cancer. The radiation will be detectable in your urine for up to 30 days following administration of the drug. It is important to minimize radiation exposure to household contacts consistent with good radiation safety practices as advised by your healthcare provider.

Please see Important Safety Information throughout and on pages 8 and 9 and full Prescribing Information.

VISIT LUTATHERA.COM ▶

Medication History

Your health care professional will typically ask about any medications you are currently taking or those you have taken in the past, and your experience with each of them. It may be helpful to write down any medications you are taking, including prescriptions, over-the-counter medicines, and vitamins.

Medication History

Name of Current Medication	Your Experience

Names of Previous Medication(s)	Your Experience

Over-the-Counter Medications

For example, vitamins, supplements, and herbs

IMPORTANT SAFETY INFORMATION (continued)

What are some important things to know about the safety of LUTATHERA? (continued)

- **Bone marrow problems:** Treatment with LUTATHERA® (lutetium Lu 177 dotatate) injection for intravenous use increases the risk of myelosuppression, a condition in which bone marrow activity is decreased, resulting in a drop in blood cell counts. You may experience blood-related side effects such as low red blood cells (anemia), low numbers of cells that are responsible for blood clotting (thrombocytopenia), and low numbers of white blood cells (neutropenia). Speak with your healthcare provider if you experience any signs or symptoms of infection, fever, chills, dizziness, shortness of breath or increased bleeding or bruising. Your healthcare provider may need to adjust or stop your treatment accordingly.

Please see Important Safety Information throughout and on pages 8 and 9 and full Prescribing Information.

You should speak to your health care professional about treatment options that may be appropriate for you.

What do you want out of your next treatment option?

Any other questions or concerns you may have?

IMPORTANT SAFETY INFORMATION (continued)

What are some important things to know about the safety of LUTATHERA? (continued)

- **Secondary bone marrow and blood cancers:** Other serious conditions that you may develop as a direct result of treatment with LUTATHERA® (lutetium Lu 177 dotatate) injection for intravenous use include blood and bone marrow disorders known as secondary myelodysplastic syndrome and cancer known as acute leukemia. Your healthcare provider will routinely check your blood cell counts and tell you if they are too low or too high.

Please see Important Safety Information throughout and on pages 8 and 9 and full Prescribing Information.

VISIT LUTATHERA.COM ▶

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Understanding LUTATHERA

Here is some important information about LUTATHERA® (lutetium Lu 177 dotatate) injection for intravenous use that might be helpful to know before talking to your health care professional. We have also provided additional space to write down other questions or thoughts you may want to discuss. If you have additional questions about LUTATHERA, please speak to your health care professional.

What Is LUTATHERA?

- LUTATHERA is a prescription treatment for adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumor (GEP-NET) that has somatostatin hormone receptors
- LUTATHERA is the first and only radioligand therapy (also known as RLT) for GEP-NET, a medicine from a class of drugs called peptide receptor radionuclide therapy (also known as PRRT)
  - LUTATHERA uses radiation to target and damage cells that are positive for the somatostatin hormone receptor, including cancer cells and neighboring cells
- LUTATHERA is given as an intravenous (IV) infusion

Write down any other questions or thoughts about this topic you may have.

IMPORTANT SAFETY INFORMATION (continued)

What are some important things to know about the safety of LUTATHERA? (continued)

- **Kidney problems:** Treatment with LUTATHERA will expose your kidneys to radiation and may impair their ability to work as normal. You may be at an increased risk for kidney problems after LUTATHERA treatment if you already have kidney impairment before treatment. In some cases, patients have experienced kidney failure after treatment with LUTATHERA. Your healthcare provider will provide you with an amino acid solution before, during, and after LUTATHERA to help protect your kidneys. You should stay well hydrated before, during, and after your treatment. You should urinate frequently during and after administration of LUTATHERA. Your doctor will monitor your kidney function and may withhold, reduce, or stop your LUTATHERA treatment accordingly.

Please see Important Safety Information throughout and on pages 8 and 9 and full Prescribing Information.

How Does LUTATHERA Work?

LUTATHERA® (lutetium Lu 177 dotatate) injection for intravenous use is believed to work differently from most cancer medications for GEP-NET, with a 2-part approach that specifically targets and enters the cells that have somatostatin receptors, releasing energy in the form of radiation that damages them and nearby cells. In other words, LUTATHERA is a "key" that connects with the "lock" (cells containing somatostatin receptors).

Write down any other questions or thoughts about this topic you may have.

What Were the Clinical Trial Results?

In a clinical trial, 229 people with midgut NETs who received LUTATHERA in combination with 30 mg of long-acting octreotide were compared with those who received 60 mg of long-acting octreotide alone.

In the LUTATHERA group, the relative risk of cancer getting worse or death was reduced by 79% compared with people treated with 60 mg of long-acting octreotide alone.

The most common and most serious side effects of LUTATHERA included: vomiting, nausea, decreased blood cell counts, increased liver enzymes, decreased blood potassium levels, and increased blood glucose.

Write down any other questions or thoughts about this topic you may have.

IMPORTANT SAFETY INFORMATION (continued)

What are some important things to know about the safety of LUTATHERA? (continued)

- **Liver problems:** In clinical studies of LUTATHERA, less than 1% of patients were reported to have tumor bleeding (hemorrhage), swelling (edema) or tissue damage (necrosis) to the liver. If you have tumors in your liver, you may be more likely to experience these side effects. Signs that you may be experiencing liver damage include increases in blood markers called ALT, AST and GGT. Your healthcare provider will monitor your liver using blood tests and may need to withhold, reduce, or stop your LUTATHERA treatment accordingly.

Please see Important Safety Information throughout and on pages 8 and 9 and full Prescribing Information.

VISIT LUTATHERA.COM ▶

Potential Side Effects

What Are Some Important Things To Know About LUTATHERA?

All prescription medications come with safety considerations. Some considerations you should be aware of before starting LUTATHERA® (lutetium Lu 177 dotatate) injection for intravenous use relate to:

- Radiation exposure
- Bone marrow problems
- Secondary bone marrow and blood cancers
- Kidney problems
- Liver problems
- Hormonal gland problems (hormonal crisis)
- Infertility
- Embryo-fetal toxicity

What Side Effects Could I Experience With LUTATHERA?

LUTATHERA may cause side effects. Some of these side effects can be serious, and your health care professional may need to adjust or stop your treatment if you experience any of these. You should always follow the instructions of your health care professional.

In clinical trials, the most common grade 3/4 (severe) adverse reactions occurring with a greater frequency among patients receiving LUTATHERA included:

- Vomiting
- Nausea
- Decreased blood cell counts
- Increased liver enzymes
- Decreased blood potassium levels
- Increased glucose in the bloodstream

Talk to your health care professional if you experience any side effects. There are other possible side effects of LUTATHERA. For more information, and to learn more about LUTATHERA, talk to your health care professional.

IMPORTANT SAFETY INFORMATION (continued)

What are some important things to know about the safety of LUTATHERA? (continued)

- **Hormonal gland problems (carcinoid crisis):** During your treatment you may experience certain symptoms that are related to hormones released from your cancer. These symptoms may include flushing, diarrhea, difficulty breathing (bronchospasm), and low blood pressure (hypotension), and may occur during or within the 24 hours after your first LUTATHERA treatment. Your healthcare provider will monitor you closely. Speak with your healthcare provider if you experience any of these signs or symptoms.

Please see Important Safety Information throughout and on pages 8 and 9 and full Prescribing Information.

Talk to your health care professional if you have concerns or experience any side effects.

Please see additional warnings in this brochure or in the full Prescribing Information regarding pregnancy, breastfeeding, and use of birth control.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

IMPORTANT SAFETY INFORMATION (continued)

What are some important things to know about the safety of LUTATHERA? (continued)

- **Pregnancy warning:** Tell your healthcare provider if you are pregnant. LUTATHERA® (lutetium Lu 177 dotatate) injection for intravenous use can harm your unborn baby. Females should use an effective method of birth control during treatment and for 7 months after the final dose of LUTATHERA. Males with female partners should use an effective method of birth control during treatment and for 4 months after the final dose of LUTATHERA.
- **Breastfeeding warning:** You should not breastfeed during treatment with LUTATHERA and for 2.5 months after your final dose of LUTATHERA.
- **Fertility problems**: Treatment with LUTATHERA may cause infertility. This is because radiation absorbed by your testis or ovaries over the treatment period falls in the range of exposure where temporary or permanent infertility may occur.

Please see Important Safety Information throughout and on pages 8 and 9 and full Prescribing Information.

VISIT LUTATHERA.COM ▶

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Important Safety Information

What is LUTATHERA?

LUTATHERA® (lutetium Lu 177 dotatate) injection for intravenous use is a prescription medicine used to treat adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut.

IMPORTANT SAFETY INFORMATION

What are some important things to know about the safety of LUTATHERA?

LUTATHERA is associated with some serious safety considerations, and in some cases these may require your healthcare provider to adjust or stop your treatment. You should always follow your healthcare provider's instructions. Safety considerations include:

- **Radiation exposure:** Treatment with LUTATHERA will expose you to radiation which can contribute to your long-term radiation exposure. Overall radiation exposure is associated with an increased risk for cancer. The radiation will be detectable in your urine for up to 30 days following administration of the drug. It is important to minimize radiation exposure to household contacts consistent with good radiation safety practices as advised by your healthcare provider.
- **Bone marrow problems:** Treatment with LUTATHERA increases the risk of myelosuppression, a condition in which bone marrow activity is decreased, resulting in a drop in blood cell counts. You may experience blood-related side effects such as low red blood cells (anemia), low numbers of cells that are responsible for blood clotting (thrombocytopenia), and low numbers of white blood cells (neutropenia). Speak with your healthcare provider if you experience any signs or symptoms of infection, fever, chills, dizziness, shortness of breath or increased bleeding or bruising. Your healthcare provider may need to adjust or stop your treatment accordingly.
- **Secondary bone marrow and blood cancers:** Other serious conditions that you may develop as a direct result of treatment with LUTATHERA include blood and bone marrow disorders known as secondary myelodysplastic syndrome and cancer known as acute leukemia. Your healthcare provider will routinely check your blood cell counts and tell you if they are too low or too high.
- **Kidney problems:** Treatment with LUTATHERA will expose your kidneys to radiation and may impair their ability to work as normal. You may be at an increased risk for kidney problems after LUTATHERA treatment if you already have kidney impairment before treatment. In some cases, patients have experienced kidney failure after treatment with LUTATHERA. Your healthcare provider will provide you with an amino acid solution before, during, and after LUTATHERA to help protect your kidneys. You should stay well hydrated before, during, and after your treatment. You should urinate frequently during and after administration of LUTATHERA. Your doctor will monitor your kidney function and may withhold, reduce, or stop your LUTATHERA treatment accordingly.
- **Liver problems:** In clinical studies of LUTATHERA, less than 1% of patients were reported to have tumor bleeding (hemorrhage), swelling (edema) or tissue damage (necrosis) to the liver. If you have tumors in your liver, you may be more likely to experience these side effects. Signs that you may be experiencing liver damage include increases in blood markers called ALT, AST and GGT. Your healthcare provider will monitor your liver using blood tests and may need to withhold, reduce, or stop your LUTATHERA treatment accordingly.

Please see Important Safety Information throughout and on pages 8 and 9 and full Prescribing Information.

Important Safety Information (continued)

- **Hormonal gland problems (carcinoid crisis):** During your treatment you may experience certain symptoms that are related to hormones released from your cancer. These symptoms may include flushing, diarrhea, difficulty breathing (bronchospasm), and low blood pressure (hypotension), and may occur during or within the 24 hours after your first LUTATHERA® (lutetium Lu 177 dotatate) injection for intravenous use treatment. Your healthcare provider will monitor you closely. Speak with your healthcare provider if you experience any of these signs or symptoms.
- **Pregnancy warning:** Tell your healthcare provider if you are pregnant. LUTATHERA can harm your unborn baby. Females should use an effective method of birth control during treatment and for 7 months after the final dose of LUTATHERA. Males with female partners should use an effective method of birth control during treatment and for 4 months after the final dose of LUTATHERA.
- **Breastfeeding warning:** You should not breastfeed during treatment with LUTATHERA and for 2.5 months after your final dose of LUTATHERA.
- **Fertility problems:** Treatment with LUTATHERA may cause infertility. This is because radiation absorbed by your testis or ovaries over the treatment period falls in the range of exposure where temporary or permanent infertility may occur.

What are the most common side effects of LUTATHERA?

The most common and most serious side effects of LUTATHERA include: vomiting, nausea, decreased blood cell counts, increased liver enzymes, decreased blood potassium levels, and increased blood glucose.

Talk to your doctor if you experience any of these side effects. There are other possible side effects of LUTATHERA. For more information, and to learn more about LUTATHERA, talk to your doctor or healthcare provider.

What other medicines may interact with LUTATHERA?

Tell your healthcare provider if you are taking any other medications. Somatostatin analogs and corticosteroids may affect how your LUTATHERA treatment works. You should stop taking your long-acting somatostatin analog at least 4 weeks before LUTATHERA treatment. You may continue taking short-acting somatostatin analogs up to 24 hours before your LUTATHERA treatment. Avoid repeated high doses of glucocorticosteroids during treatment with LUTATHERA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Distributed by: Advanced Accelerator Applications, NJ 07041

Please see Important Safety Information throughout and on pages 8 and 9 and full Prescribing Information.

Want to find out more about LUTATHERA® (lutetium Lu 177 dotatate) injection for intravenous use? Visit us at:

Facebook.com/LUTATHERA

Twitter.com/LUTATHERA (@LUTATHERA)

Advanced Accelerator Applications
A Novartis Company

VISIT LUTATHERA.COM ▶

Advanced Accelerator Applications USA, Inc
57 East Willow Street, Millburn, NJ 07041

128042 | 9/21

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use